HomeCompareCLSD vs JNJ

CLSD vs JNJ: Dividend Comparison 2026

CLSD yields 487.80% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLSD wins by $50753.86M in total portfolio value
10 years
CLSD
CLSD
● Live price
487.80%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50753.89M
Annual income
$36,168,404,531.85
Full CLSD calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — CLSD vs JNJ

📍 CLSD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLSDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLSD + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLSD pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLSD
Annual income on $10K today (after 15% tax)
$41,463.41/yr
After 10yr DRIP, annual income (after tax)
$30,743,143,852.07/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, CLSD beats the other by $30,743,139,814.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLSD + JNJ for your $10,000?

CLSD: 50%JNJ: 50%
100% JNJ50/50100% CLSD
Portfolio after 10yr
$25376.96M
Annual income
$18,084,204,640.87/yr
Blended yield
71.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CLSD
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
Altman Z
-48.3
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLSD buys
0
JNJ buys
0
No recent congressional trades found for CLSD or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLSDJNJ
Forward yield487.80%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$50753.89M$30.5K
Annual income after 10y$36,168,404,531.85$4,749.88
Total dividends collected$49478.61M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CLSD vs JNJ ($10,000, DRIP)

YearCLSD PortfolioCLSD Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$59,480$48,780.49$10,594$274.49+$48.9KCLSD
2$334,811$271,167.03$11,294$360.69+$323.5KCLSD
3$1,784,770$1,426,522.08$12,133$476.91+$1.77MCLSD
4$9,016,553$7,106,848.63$13,156$635.42+$9.00MCLSD
5$43,202,271$33,554,559.81$14,432$854.61+$43.19MCLSD
6$196,483,123$150,256,693.49$16,056$1,162.76+$196.47MCLSD
7$848,895,486$638,658,543.63$18,175$1,604.53+$848.88MCLSD
8$3,487,095,949$2,578,777,778.75$21,009$2,252.68+$3487.07MCLSD
9$13,631,297,985$9,900,105,319.66$24,911$3,229.73+$13631.27MCLSD
10$50,753,893,375$36,168,404,531.85$30,458$4,749.88+$50753.86MCLSD

CLSD vs JNJ: Complete Analysis 2026

CLSDStock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Full CLSD Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CLSD vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLSD vs SCHDCLSD vs JEPICLSD vs OCLSD vs KOCLSD vs MAINCLSD vs ABBVCLSD vs MRKCLSD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.